Question · asked by 1 review

L‐ornithine L‐aspartate vs probiotic: Non‐serious adverse events assessed using ICH‐GCP

Population
people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy; regardless of sex, age, aetiology, and severity of the underlying liver disease, or the presence of identified precipitating factors
Intervention
L‐ornithine L‐aspartate
Comparison
probiotic
Outcome
Non‐serious adverse events assessed using ICH‐GCP

The review found no eligible studies for this question.

What each review found

Current versions only
FindingEffectStudiesGRADE certainty
L‐ornithine L‐aspartate vs probiotic
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic…
The review found no eligible studies for this question.
L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis (2018) · Cochrane Headline outcomes only
no estimate extractedNot reportedNo studies found

Findings are shown side by side, never pooled across reviews.

The reviews

ReviewSearched up toIncluded studiesAMSTAR 2
L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis
2018 · Cochrane Headline outcomes only
Not reportedNot extractedNot assessed

The same intervention and outcome, asked in another population or against another comparator.

How reviews are matched to this question

Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.